GlassScriptPhysician profile
Donna L Rector
NPI 1790869634
$4,291.24
in general payments reported to CMS, 2019-2025
36 companies · $774 in 2025
The $774 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $610 · 2022: $1,067 · 2023: $956 · 2024: $884 · 2025: $774.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,614.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,613.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $770.91 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $627.24 | 2021-2025 | Jardiance |
| Novo Nordisk INC | $535.06 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $444.77 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $238.41 | 2022-2024 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $224.03 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $177.62 | 2021-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $171.44 | 2021-2023 | |
| Astellas Pharma US INC | $111.12 | 2021-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $100.53 | 2021-2024 | |
| Ibsa Pharma INC. | $71.07 | 2021-2025 | Licart, Tirosint, Flector |
| Amarin Pharma, INC. | $68.67 | 2021 | |
| Seqirus USA INC | $63.96 | 2022-2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Sumitomo Pharma America, INC. | $63.48 | 2023-2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $62.92 | 2021-2024 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $59.25 | 2025 | Yupelri |
| Kowa Pharmaceuticals America, INC. | $49.45 | 2022-2023 | Seglentis |
| Neurocrine Biosciences, INC. | $48.25 | 2023-2024 | Ingrezza, Ongentys |
| Exact Sciences Corporation | $41.29 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Dynavax Technologies Corporation | $39.61 | 2023-2024 | Heplisav-B |
| Novartis Pharmaceuticals Corporation | $34.74 | 2022 | |
| Merck Sharp & Dohme LLC | $32.38 | 2021 | |
| Rgh Enterprises LLC | $29.89 | 2024 | |
| Verona Pharma, INC. | $28.90 | 2025 | Ohtuvayre |
| Dexcom, INC. | $21.77 | 2023 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.36 | 2025 | Xifaxan |
| Mylan Specialty L.P. | $19.29 | 2024 | Yupelri |
| Axsome Therapeutics, INC. | $16.46 | 2023 | Auvelity |
| Amneal Pharmaceuticals LLC | $16.45 | 2025 | Unithroid |
| Amgen INC. | $16.28 | 2025 | Evenity |
| Renalytix Ai, INC. | $16.22 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Phathom Pharmaceuticals, INC. | $15.00 | 2025 | Voquezna |
| Esperion Therapeutics, INC. | $14.27 | 2025 | Nexletol |
| Janssen Scientific Affairs, LLC | $14.12 | 2024 | Xarelto |
| Biohaven Pharmaceuticals, INC. | $12.52 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $12.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Rector listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.